Response of letter to the editor on Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy
© The Author(s). 2017
Received: 31 October 2017
Accepted: 6 November 2017
Published: 6 December 2017
The original article was published in Journal of Intensive Care 2017 5:58
In a letter to the editor, Raineri SM et al. have given an insight of another dimension of procalcitonin (PCT) use as a diagnostic tool in invasive candidiasis. But based on our preliminary information, PCT is reported as unconventional modes of diagnosis approach which yet to prove its stand-alone biomarker properties for invasive candidiasis.
Letter to the editor
In our recent paper in Journal of Intensive Care, we presented a prototypical explanation of procalcitonin (PCT) use as a diagnostic marker in early detection of sepsis and septic shock due to bacterial infections. We concluded that combination of emerging new biomarkers with PCT could be used in terms of good clinical judgement based on which antimicrobial therapy may suggest, thus reducing the prescription and dosage of antibiotic treatment. In addition, we also suggested that PCT alone might not be effective for accurate diagnosis. Our findings in our article are limited to infection-related bacterial sepsis.
In a letter to the editor, SM Raineri and colleagues, suggest that PCT is useful in suspected invasive candidiasis.
As per Raineri SM et al., PCT may also serve as an effective tool for invasive candidiasis . Based on Charles et al. (2006), PCT level is significantly low in patients with candidemia (median 0.65 ng/ml) compared to those with bacteremia (median 9.75 ng/ml). PCT level higher than 5.5 ng/ml demonstrated a 100% negative predictive value (NPV) and 65% positive predictive value (PPV) for sepsis caused by Candida spp. . With these findings, we also believe that the level of PCT expression may vary in such conditions. But the limiting factor is that the expression of PCT levels in candidemia is very less in comparison with bacterial infections. Hence, the detection of PCT requires much more sensitive diagnostic methods. A successful biomarker for diagnostic use should be elevated in response to the pathogen at the earliest with detectable threshold quantities. Clearly, more research is needed to realize ‘high certainty of evidence-based recommendations’.
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Raineri SM, Cortegiani A, Vitale F, Iozzo P, Giarratano A. Procalcitonin for the diagnosis of invasive candidiasis: what is the evidence? J Intensive Care. 2017;5:58.View ArticlePubMedPubMed CentralGoogle Scholar
- Charles PE, Dalle F, Aho S, Quenot J-P, Doise J-M, Aube H, Olsson N-O, Blettery B. Serum procalcitonin measurement contribution to the early diagnosis of candidemia in critically ill patients. Intensive Care Med. 2006;32:1577–83.View ArticlePubMedGoogle Scholar